Superworth

Vanda Pharmaceuticals price to book ratio VNDA

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
1.1×
10-year median
1.5×
Against its 10-year history
34th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 6.9×
Peer median
2.2×

Vanda Pharmaceuticals' price to book ratio is 1.1× as of Oct 23, 2026.

That is below its ten-year median of 1.5×, lower than on 66% of days in the last ten years.

Over that time it ranged from 0.4× in Nov 2023 to 6.9× in Mar 2018.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.1×0.9×1.6×
20250.9×0.4×0.9×
20240.5×0.4×0.7×
20230.4×0.4×0.8×
20220.8×0.8×1.7×
20211.8×1.7×2.5×
20201.6×1.1×2.1×
20192.2×2.0×6.2×
20185.1×3.3×6.9×
20175.2×4.4×6.3×
20165.4×2.4×6.0×
20152.7×2.4×4.0×
201422.7×7.5×26.2×
20138.1×4.1×73.4×
20126.6×3.3×7.1×
20113.5×3.3×4.8×

Against its peers

Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
VNDAVanda Pharmaceuticals1.1×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
LFVNLifevantage2.2×
ABUSArbutus Biopharma3.2×
SPROSpero Therapeutics1.5×
Peer median2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Vanda Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.